Halozyme upgraded to Buy from Neutral at UBS UBS transitioned coverage on Halozyme with a Buy rating from a Neutral rating. The firm upgraded shares due to valuation and is more bullish on the PEGPH20 program following the recently removed clinical hold and believes the Herceptin-SC launch is tracking well and provides near-term support and strong uptake. Price target raised to $16 from $%14.
News For HALO From The Last 14 Days
Check below for free stories on HALO the last two weeks.
Halozyme resumes enrollment and dosing of patients for PEGPH20 Phase 2 trial Halozyme Therapeutics announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: Altria Group (MO) initiated with an Outperform at Cowen... Berkshire Hills Bancorp (BHLB) initiated with a Hold at Jefferies... CGI Group (GIB) initiated with an Outperform at Credit Suisse... Halozyme (HALO) initiated with an Overweight at JPMorgan... Lorillard (LO) initiated with an Underperform at Cowen... MacroGenics (MGNX) initiated with an Outperform at Oppenheimer... Philip Morris (PM) initiated with a Market Perform at Cowen... Prothena (PRTA) initiated with an Outperform at Oppenheimer... Reynolds American (RAI) initiated with a Market Perform at Cowen... Seventy Seven Energy (SSE) initiated with a Buy at Wunderlich... SouFun (SFUN) initiated with a Neutral at Macquarie... Sprouts Farmers Markets (SFM) initiated with a Neutral at Longbow... Sterling Bancorp (STL) initiated with a Buy at Jefferies... Xencor (XNCR) initiated with an Outperform at Oppenheimer... YPF (YPF) initiated with a Neutral at JPMorgan... iGATE (IGTE) initiated with an Outperform at William Blair.